WallStSmart

Berkshire Hathaway Inc (BRK-A)vsDrugs Made In America Acquisition II Corp. Ordinary Shares (DMII)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

BRK-A leads profitability with a 18.0% profit margin vs 0.0%. BRK-A trades at a lower P/E of 15.3x. BRK-A earns a higher WallStSmart Score of 51/100 (C-).

BRK-A

Buy

51

out of 100

Grade: C-

Growth: 3.3Profit: 7.5Value: 5.0Quality: 8.0
Piotroski: 3/9Altman Z: 2.46

DMII

Avoid

30

out of 100

Grade: F

Growth: 4.3Profit: 3.5Value: 4.0Quality: 5.0

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BRK-A6 strengths · Avg: 9.2/10
Market CapQuality
$1.02T10/10

Mega-cap, among the largest globally

Price/BookValuation
1.4x10/10

Reasonable price relative to book value

Operating MarginProfitability
33.0%10/10

Strong operational efficiency at 33.0%

Debt/EquityHealth
0.219/10

Conservative balance sheet, low leverage

P/E RatioValuation
15.3x8/10

Attractively priced relative to earnings

Free Cash FlowQuality
$4.99B8/10

Generating 5.0B in free cash flow

DMII0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

BRK-A4 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
9.682/10

Expensive relative to growth rate

Revenue GrowthGrowth
-0.7%2/10

Revenue declined 0.7%

EPS GrowthGrowth
-2.5%2/10

Earnings declined 2.5%

DMII4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$637.64M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : BRK-A

The strongest argument for BRK-A centers on Market Cap, Price/Book, Operating Margin. Profitability is solid with margins at 18.0% and operating margin at 33.0%.

Bull Case : DMII

DMII has a balanced fundamental profile.

Bear Case : BRK-A

The primary concerns for BRK-A are Piotroski F-Score, PEG Ratio, Revenue Growth.

Bear Case : DMII

The primary concerns for DMII are Revenue Growth, EPS Growth, Market Cap. A P/E of 66.7x leaves little room for execution misses.

Key Dynamics to Monitor

BRK-A profiles as a declining stock while DMII is a value play — different risk/reward profiles.

DMII is growing revenue faster at 0.0% — sustainability is the question.

BRK-A generates stronger free cash flow (5.0B), providing more financial flexibility.

Monitor INSURANCE - DIVERSIFIED industry trends, competitive dynamics, and regulatory changes.

Bottom Line

BRK-A scores higher overall (51/100 vs 30/100), backed by strong 18.0% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Berkshire Hathaway Inc

FINANCIAL SERVICES · INSURANCE - DIVERSIFIED · USA

Berkshire Hathaway Inc. is an American multinational conglomerate holding company headquartered in Omaha, Nebraska, United States. The company wholly owns GEICO, Duracell, Dairy Queen, BNSF, Lubrizol, Fruit of the Loom, Helzberg Diamonds, Long & Foster, FlightSafety International, Pampered Chef, Forest River, and NetJets, and also owns 38.6% of Pilot Flying J; and significant minority holdings in public companies Kraft Heinz Company (26.7%), American Express (18.8%), The Coca-Cola Company (9.32%), Bank of America (11.9%), and Apple (6.3%).

Visit Website →

Drugs Made In America Acquisition II Corp. Ordinary Shares

FINANCIAL SERVICES · SHELL COMPANIES · USA

Drugs Made In America Acquisition II Corp. (DMII) is a special purpose acquisition company (SPAC) focused on merging with innovative firms within the pharmaceuticals and biotechnology sectors to enhance domestic drug manufacturing capabilities. Leveraging the extensive expertise of its management team, DMII identifies and executes strategic transactions that align with rising market demands and prioritize sustainable practices. Through its commitment to fostering resilient supply chains and advancing U.S. healthcare self-sufficiency, DMII aims to deliver sustained value for its shareholders and contribute to the long-term growth of the American pharmaceutical landscape.

Want to dig deeper into these stocks?